How the FDA Regulates Apps Used With Prescription Drugs

Prescription medicines increasingly arrive with optional apps, connected injectors, reminders and coaching tools. The FDA does not treat every function in the same way. Its framework starts by asking who distributes the software, what the user sees, whether a device supplies data and whether credible evidence shows a meaningful clinical benefit.

Which software is covered?

The guidance covers software distributed by or on behalf of a drug sponsor when its output supplements, explains or otherwise relates to the sponsor’s prescription medicine. Independent apps that a sponsor neither distributes nor directs patients to use fall outside this particular guidance, although other laws may still apply.

Connected versus standalone functions

A device-connected function receives data directly from a device component, such as an autoinjector that sends use information to an app. The drug’s prescribing information will generally describe that connection. A standalone function relies on user-entered data or works without a connected device. It normally appears in prescribing information only when it is essential for safe and effective use or when adequate studies show a meaningful improvement in a clinical outcome.

What counts as labeling?

The screens, alerts, sounds and messages an app presents to users can count as drug labeling. If the content is required labeling, FDA review and approval rules apply. If it is promotional labeling, it must still be truthful, balanced and submitted under post-market reporting requirements.

What the framework does not prove

An app’s inclusion alongside an approved medicine is not automatic evidence that the software improves outcomes. Device rules may also apply separately, and privacy questions are governed by other frameworks. Product-specific claims still depend on the quality of the supporting evidence.